The company reached a break-even point for the three months ending July 31, a significant improvement from the $19 million loss recorded during the same period last year. International markets served as the primary engine for this performance, contributing $603 million in sales, while U.S. operations saw a 13% increase to $240 million.

Chief Executive Que Dallara described the results as a strong opening for the fiscal year. Bolstered by this performance, management raised its full-year organic revenue growth outlook to approximately 10.5%, edging past the previous 10% forecast. The company intends to leverage its automated insulin delivery platforms to sustain this trajectory and deliver further shareholder value.